Cargando…

Real-World Evidence on Palliative Gemcitabine and Oxaliplatin (GemOx) Combination Chemotherapy in Advanced Biliary Tract Cancer

SIMPLE SUMMARY: Cancers of the biliary tract are rare but severe with high mortality rates. Randomised controlled trials suggest that chemotherapies such as gemcitabine and oxaliplatin (GemOx) may relieve symptoms and prolong life, but less is known on the efficacy and safety of such regimens in rea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lagenfelt, Hanna, Blomstrand, Hakon, Elander, Nils O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8304000/ https://www.ncbi.nlm.nih.gov/pubmed/34298723 http://dx.doi.org/10.3390/cancers13143507

Ejemplares similares

Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer
por: Blomstrand, Hakon, et al.
Publicado: (2019)

Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer
por: Blomstrand, Hakon, et al.
Publicado: (2021)

Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
por: Chen, Xiaofeng, et al.
Publicado: (2020)

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
por: Demols, A, et al.
Publicado: (2006)

Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer
por: Harder, J, et al.
Publicado: (2006)

Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients
por: Vici, Patrizia, et al.
Publicado: (2013)

Adjuvant Gemcitabine-Oxaliplatin (GEMOX) after Curative Surgery in High-risk Patients with Cholangiocarcinoma
por: Paule, Bernard, et al.
Publicado: (2010)

Real World Evidence on Second-Line Palliative Chemotherapy in Advanced Pancreatic Cancer
por: Gränsmark, Emma, et al.
Publicado: (2020)

Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature
por: Soni, Kishan, et al.
Publicado: (2020)

Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review
por: Fiteni, Frédéric, et al.
Publicado: (2014)

Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel
por: Blomstrand, Hakon, et al.
Publicado: (2020)

Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study
por: André, T, et al.
Publicado: (2008)

Transcatheter arterial chemoembolization with gemcitabine and oxaliplatin for the treatment of advanced biliary tract cancer
por: Zhao, Qing, et al.
Publicado: (2015)

Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer
por: Zhu, Chengpei, et al.
Publicado: (2023)

Outcomes of patients treated with SVILE vs. P-GemOx for extranodal natural killer/T-cell lymphoma, nasal type: a prospective, randomized controlled study
por: Wei, Liqiang, et al.
Publicado: (2020)

Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma
por: Wang, Jing-hua, et al.
Publicado: (2016)

A Retrospective Case Series Of High-Intensity Focused Ultrasound (HIFU) In Combination With Gemcitabine And Oxaliplatin (Gemox) On Treating Elderly Middle And Advanced Pancreatic Cancer
por: Tao, Shuang-fen, et al.
Publicado: (2019)

Successful Outcome of Programmed Death 1 Blockade Plus GemOx for Epstein-Barr Virus-Associated Primary Nodal T/NK Cell Lymphoma: A Case Report
por: Xia, Liang, et al.
Publicado: (2021)

EGFR Target Therapy Combined with Gemox for Advanced Biliary Tract Cancers: a Meta-analysis based on RCTs
por: Cai, Wen, et al.
Publicado: (2018)

Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers
por: Chen, Ruijia, et al.
Publicado: (2022)

Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine—A Randomized Phase II Trial
por: Markussen, Alice, et al.
Publicado: (2020)

Safety and efficacy of GEMOX plus donafenib and tislelizumab as first‐line therapy for advanced epithelial malignant biliary tract cancer
por: Wang, Longrong, et al.
Publicado: (2023)

A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers
por: Goff, Laura W., et al.
Publicado: (2016)

Immuno-genomic-radiomics to predict response of biliary tract cancer to camrelizumab plus GEMOX in a single-arm phase II trial
por: Liu, Qiu-Ping, et al.
Publicado: (2023)

Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer
por: Hezel, A F, et al.
Publicado: (2014)

Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer
por: Thol, Felix, et al.
Publicado: (2021)

Complete Radiologic Response of Metastatic Pancreatic Ductal Adenocarcinoma to Microwave Ablation Combined with Second-Line Palliative Chemotherapy
por: Blomstrand, Hakon, et al.
Publicado: (2020)

Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer
por: Kim, Seung Tae, et al.
Publicado: (2015)

Gemcitabine and S-1 Combination Chemotherapy in Patients with Advanced Biliary Tract Cancer: A Retrospective Study
por: Mita, Kazuhito, et al.
Publicado: (2010)

Effect of midkine on gemcitabine resistance in biliary tract cancer
por: Lu, Yongliang, et al.
Publicado: (2018)

Efficacy and safety of a triple combination of atezolizumab, bevacizumab plus GEMOX for advanced biliary tract cancer: a multicenter, single-arm, retrospective study
por: Wang, Kang, et al.
Publicado: (2023)

Comparison of the Efficacy between Gemcitabine-Cisplatin and Capecitabine-Cisplatin Combination Chemotherapy for Advanced Biliary Tract Cancer
por: Lee, Jieun, et al.
Publicado: (2015)

Prevalence of CTR1 and ERCC1 Polymorphisms and Response of Biliary Tract Cancer to Gemcitabine-Platinum Chemotherapy
por: Pongmaneratanakul, Skolchart, et al.
Publicado: (2017)

Gemcitabine, oxaliplatin and dexamethasone (GemDOx) as salvage therapy for relapsed or refractory diffuse large B-cell lymphoma and peripheral T-cell lymphoma
por: Shen, Qiu-Dan, et al.
Publicado: (2021)

Prolonged Complete Response after GEMOX Chemotherapy in a Patient with Advanced Fibrolamellar Hepatocellular Carcinoma
por: Gras, Pauline, et al.
Publicado: (2012)

Stevens-Johnson Syndrome Patient Received Combination Chemotherapy Gemcitabine, Cisplatin, and 5-FU for Biliary Tract Cancer
por: Aznab, Mozaffar, et al.
Publicado: (2016)

Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113
por: Ueno, Makoto, et al.
Publicado: (2021)

A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract
por: Graham, J. S., et al.
Publicado: (2016)

Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer
por: Kim, Seung Tae, et al.
Publicado: (2015)

Real World First-Line Treatments and Outcomes of Nab-Paclitaxel Plus Gemcitabine, mFOLFIRINOX and GEMOX in Unresectable Pancreatic Cancer from a Chinese Single Institution
por: Quan, Qi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rf2qk0t1jlhunlpqfjpcc8sq3a